top stories

Top Har­vard chemist caught up in FBI’s 'T­hou­sand Tal­ents' drag­net, ac­cused of ly­ing about Chi­nese con­nec­tions, pay

3 hours ago
China

Eye­ing a trio of tri­al ini­ti­a­tions, Jim Wilson's gene ther­a­py start­up woos Bruce Gold­smith from Deer­field as CEO

6 hours ago
Cell/Gene Tx
People

Ex-No­var­tis CEO Joe Jimenez is tak­ing an­oth­er crack at open­ing a new chap­ter in his ca­reer — and that in­cludes a ...

16 hours ago
People
R&D

Flag­ship's first ven­ture of 2020 is out, and it's all about sperm

11 hours ago
Startups

Latest

Pfiz­er ax­es 6 ear­ly to late-stage can­cer stud­ies from the pipeline — with one oth­er cut for sick­le cell dis­ease

11 hours ago
R&D

UP­DAT­ED: In­cyte scores much need­ed PhI­II suc­cess — and of course it’s de­liv­ered by rux­oli­tinib

12 hours ago
R&D

Sanofi/Re­gen­eron Dupix­ent; Alk­er­mes' an­tipsy­chot­ic get dates with the FDA; Con­cert wins re­prieve in In­cyte patent ...

12 hours ago
Protocols

Can we make the an­tibi­ot­ic mar­ket great again?

12 hours ago
R&D

The FDA un­veils a new reg­u­la­to­ry frame­work to speed along gene ther­a­pies, re­ward­ing the lead­ing play­ers

13 hours ago
Bioregnum

Mike Bloomberg joins a grow­ing cho­rus of De­mo­c­ra­t­ic pres­i­den­tial can­di­dates threat­en­ing to go af­ter drug patents

15 hours ago
People
Pharma
see latest stream
People

The FTC and New York state ac­cuse Mar­tin Shkre­li of run­ning a drug mo­nop­oly. They plan to squash it — and ...

Yesterday

Ku­ra co-founder heads to Asian mul­ti-na­tion­al as biotech eyes the goal posts for lead drug

4 days ago

'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

Last week
Startups

Bruce Booth and Saman­tha Truex's lat­est ven­ture aims just above Hu­mi­ra

Yesterday

Mer­ck KGaA spin­out gets first fund­ing to bring dual-act­ing can­cer mol­e­cules in­to the clin­ic

5 days ago

French-Bel­gian biotech banks €20M to break ground in blood-splat­tered field of ther­a­peu­tic can­cer vac­cines

6 days ago
Deals

Af­ter a brief break, As­traZeneca is back at di­vest­ing — hand­ing off hy­per­ten­sion meds for $350M

Yesterday

UP­DAT­ED: Ab­b­Vie and Al­ler­gan di­vesti­tures are in, and an old As­traZeneca drug comes home

Yesterday

Who knew? Der­mi­ra’s board kept watch as its stock price tracked Eli Lil­ly’s se­cret bid­ding on a $1.1B buy­out

2 days ago
IPOs

Brex­it fears, Wood­ford woes over­shad­owed UK biotech and cut 2019 fi­nanc­ing by al­most half

6 days ago

First Chi­nese biotech on Nas­daq in two years draws $104M

Last week

Shoot­ing for $100M IPO, Schrödinger takes the wraps off its five in­ter­nal drugs and dis­clos­es deal de­tails

3 weeks ago

Premium storiesSee all

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of ...

Last week
People
R&D

Watch live: End­points at #JPM20

3 weeks ago

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the ...

3 weeks ago
Deals

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 weeks ago
Pharma
Special

Don't missSee all

UP­DAT­ED: Ac­celeron res­ur­rects block­buster hopes for so­tater­cept with pos­i­tive PhII — and shares rock­et up

Yesterday
R&D

Civi­ca and Blue Cross Blue Shield launch new ven­ture to low­er gener­ic prices

Yesterday
R&D

Short at­tack­er Sahm Ad­ran­gi draws crosshairs over a fa­vorite of Sanofi’s new CEO — with PhII da­ta loom­ing

Yesterday
R&D

A $1B-plus drug stum­bles in­to an­oth­er big PhI­II set­back — this time flunk­ing fu­til­i­ty test — as FDA hold re­mains ...

4 days ago
R&D

Endpoints Standouts

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 weeks ago
Pharma
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

2 months ago
People
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

Last month
Publisher's note

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

3 months ago

Peer review See all

Jan
24

Di­a­betes-fo­cused Pox­el names Eli Lil­ly vet David Moller as CSO; Ac­celeron's CBO hops ship to lead start­up

Jan
17

Pe­ter Ciriel­lo takes over the reins at Vy­gon USA; Mirum Phar­ma­ceu­ti­cals taps Ian Clements to the role of CFO

Jan
10

Eli Lil­ly vet jumps aboard Po­laris Part­ners; Mi­rati shakes up its lead­er­ship team with new hires and pro­mo­tions

Jan
3

IQVIA vet takes the helm at Chi­na's Foun­tain Med­ical; Michael Nazak pro­mot­ed to CFO post at Aridis

Dec
20

Bill Lund­berg takes over the reins at Merus; For­mer Akcea COO Jef­frey Gold­berg takes the helm of Im­mu­ni­tas

R&D channel feed

4 days ago

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Just weeks af­ter Mer­ck­'s star check­point in­hibitor Keytru­da se­cured FDA ap­proval for a sub­set of blad­der can­cer pa­tients, Swiss com­peti­tor Roche's Tecen­triq has failed in a piv­otal blad­der ...

READ MORE

Mer­ck KGaA match­es lofty R&D goals with €250M in­vest­ment in­to a new clin­i­cal man­u­fac­tur­ing site in Switzer­land

Yesterday

Breast can­cer ap­proval in tow, As­traZeneca, Dai­ichi armed an­ti­body scores in key gas­tric can­cer study

Yesterday
Pharma
latest in R&D

Sor­ren­to shrugs off an anony­mous pri­vate eq­ui­ty group’s $1B of­fer to buy the com­pa­ny

Yesterday

As­traZeneca makes case for use of blood thin­ner Bril­in­ta in stroke pa­tients

Yesterday
Pharma

Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st PhI­II

5 days ago

Pas­cal So­ri­ot and As­traZeneca com­mit to ze­ro-car­bon by 2025, car­bon-neu­tral by 2030. Where's the rest of Phar­ma?

5 days ago

UP­DAT­ED: New play­ers are jump­ing in­to the scram­ble to de­vel­op a vac­cine as pan­dem­ic pan­ic spreads fast

5 days ago
see latest stories

Pharma channel feed

16 hours ago

J&J's Spra­va­to gets no love from NICE, jeop­ar­diz­ing its prospects in the UK

UK's cost-ef­fec­tive­ness watch­dog NICE is tak­ing the same track laid out by ICER — J&J's phar­ma­ceu­ti­cal ver­sion of the hal­lu­cino­genic anes­thet­ic ke­t­a­mine, Spra­va­to, is low ...

READ MORE

Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

4 days ago

Tri­fec­ta of sick­le cell dis­ease ther­a­pies ex­tend life ex­pectan­cy, but are not cost-ef­fec­tive — ICER

4 days ago
latest in Pharma

Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

4 days ago
Regulatory

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

4 days ago
Regulatory

2019 a 'trans­for­ma­tive year' for phar­ma M&A. Is that a good thing?

4 days ago
Deals

Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

5 days ago
China

Wuhan virus out­break trig­gers in­evitable small-biotech ral­ly

6 days ago
see latest stories